Capecitabine for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Apr 2019: Trial registered, NCT03907475
  2. 16 Jul 2019: Trial started, NCT03907475

The trials

NCT03907475: Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

State
Under way
Phase
Phase 2
People
115 planned
Started
16 Jul 2019
Primary completion
1 Jun 2027
Arms
Arm IV (capecitabine, durvalumab)
Results
None posted
  1. 9 Apr 2019: Trial registered
  2. 16 Jul 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Capecitabine accord, Capecitabine medac, Capecitabine sun, Capecitabine teva, Ecansya, Xeloda.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.